Richard E. Chaisson

Richard E. Chaisson's AcademicInfluence.com Rankings

Richard E. Chaisson

Medical

#1350

World Rank

#1677

Historical Rank

Public Health

#162

World Rank

#169

Historical Rank

Epidemiology

#184

World Rank

#196

Historical Rank

medical Degrees

Richard E. Chaisson

Philosophy

#4336

World Rank

#6815

Historical Rank

Logic

#1822

World Rank

#2665

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Richard E. Chaisson's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Richard E. Chaisson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard E. Chaisson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. (1997) (2876)
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy (1999) (2106)
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. (2003) (1916)
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. (2000) (998)
Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions (1999) (893)
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. (2016) (832)
Tuberculosis and diabetes mellitus: convergence of two epidemics. (2009) (832)
Three months of rifapentine and isoniazid for latent tuberculosis infection. (2011) (772)
Cocaine use and HIV infection in intravenous drug users in San Francisco. (1989) (577)
Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections (2002) (568)
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. (1992) (546)
Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort (1988) (540)
Hepatitis C and progression of HIV disease. (2002) (497)
Latent Mycobacterium tuberculosis infection. (2015) (490)
Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. (1991) (486)
Natural history of HIV infection in the era of combination antiretroviral therapy. (1999) (484)
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries (2015) (477)
Guidelines for preventing opportunistic infections among HIV-infected persons - 2002 (2002) (474)
Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. (1987) (467)
Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa (2009) (421)
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial (2002) (386)
Adherence to Nonnucleoside Reverse Transcriptase InhibitorBased HIV Therapy and Virologic Outcomes (2007) (380)
Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. (1993) (366)
Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis (2012) (364)
New regimens to prevent tuberculosis in adults with HIV infection. (2011) (346)
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic (2002) (331)
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil (2007) (327)
Racial differences in the use of drug therapy for HIV disease in an urban community. (1994) (322)
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial (2009) (311)
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. (2004) (307)
Race, sex, drug use, and progression of human immunodeficiency virus disease. (1995) (305)
Adherence to Highly Active Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African Adults (2006) (304)
Natural History of Opportunistic Disease in an HIV-Infected Urban Clinical Cohort (1996) (296)
Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. (1998) (295)
Active case finding of tuberculosis: historical perspective and future prospects. (2005) (276)
Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV‐1 Infection (2001) (273)
Zidovudine and the natural history of the acquired immunodeficiency syndrome. (1991) (270)
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. (2016) (267)
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection (1998) (265)
Delayed tuberculosis diagnosis and tuberculosis transmission. (2006) (258)
Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. (2004) (257)
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. (2009) (256)
Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. (1987) (256)
Human immunodeficiency virus infection in tuberculosis patients. (1990) (249)
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort (2009) (242)
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. (2006) (238)
Tuberculosis drug resistance: a global threat. (2003) (233)
Anemia and survival in HIV infection. (1998) (220)
Eleven years of community-based directly observed therapy for tuberculosis. (1995) (219)
From magic bullets back to the Magic Mountain: the rise of extensively drug-resistant tuberculosis (2007) (216)
Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. (1995) (215)
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. (2004) (214)
Building a tuberculosis-free world: The Lancet Commission on tuberculosis (2019) (214)
Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. (2004) (212)
Treatment Supporter to Improve Adherence to Antiretroviral Therapy in HIV-Infected South African Adults: A Qualitative Study (2006) (210)
Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model (2007) (208)
Incidence of salmonellosis in patients with AIDS. (1987) (205)
Tuberculosis in Africa--combating an HIV-driven crisis. (2008) (204)
A trial of mass isoniazid preventive therapy for tuberculosis control. (2014) (200)
Impact of opportunistic disease on survival in patients with HIV infection (1998) (187)
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir (2004) (186)
Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy (2001) (183)
One Month of Rifapentine plus Isoniazid to Prevent HIV‐Related Tuberculosis (2019) (182)
Paradoxical worsening of tuberculosis in HIV-infected persons. (2001) (174)
Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B (2007) (173)
Tuberculosis and human immunodeficiency virus infection. (1989) (167)
Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. (2006) (167)
Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. (1992) (165)
Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection (2015) (160)
HIV infection-related tuberculosis: clinical manifestations and treatment. (2010) (158)
Cryptosporidiosis in patients with AIDS: correlates of disease and survival. (1998) (153)
Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. (1996) (153)
Moxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis (1999) (148)
Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. (2005) (147)
HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy (2001) (145)
HIV/AIDS and Antiretroviral Treatment Knowledge, Attitudes, Beliefs, and Practices in HIV-Infected Adults in Soweto, South Africa (2005) (145)
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. (2008) (143)
Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection (1991) (141)
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic: Mycobacterium avium complex disease in patients with HIV infection (1997) (140)
Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. (1995) (139)
Diagnostic Accuracy of a Urine Lipoarabinomannan Test for Tuberculosis in Hospitalized Patients in a High HIV Prevalence Setting (2009) (138)
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. (2021) (138)
Body mass index and risk of tuberculosis and death (2010) (136)
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. (2006) (133)
Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics (2012) (132)
Costs of HIV medical care in the era of highly active antiretroviral therapy. (1999) (131)
Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. (1993) (131)
Routine prenatal screening for HIV infection (1991) (131)
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. (2009) (131)
T-SPOT.TB responses during treatment of pulmonary tuberculosis (2009) (128)
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection (2005) (128)
Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. (1996) (127)
Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. (2002) (125)
Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence (2011) (123)
Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study (2007) (122)
Infectious complications with respiratory pathogens despite ciprofloxacin therapy. (1991) (121)
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. (2003) (121)
Prophylaxis for Opportunistic Infections in Patients with HIV Infection (1994) (121)
USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. (1995) (120)
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons (2016) (119)
Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. (1991) (118)
Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. (1996) (117)
Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. (2000) (116)
The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. (1998) (115)
Survival patterns of the first 500 patients with AIDS in San Francisco. (1988) (113)
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. (1999) (113)
Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. (2001) (111)
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? (2003) (109)
Nontuberculous mycobacteria: defining disease in a prospective cohort of South African miners. (1999) (108)
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. (2013) (107)
Projections of AIDS morbidity and mortality in San Francisco. (1990) (106)
A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. (2001) (106)
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. (1991) (103)
Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. (1991) (103)
Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. (1996) (103)
The Effect of HAART and HCV Infection on the Development of Hyperglycemia Among HIV‐Infected Persons (2003) (102)
Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine. (1991) (101)
Contribution of reinfection to recurrent tuberculosis in South African gold miners. (2008) (101)
Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. (2003) (99)
Significant changes in HIV antigen level in the serum of patients treated with azidothymidine. (1986) (97)
Community-based targeted case finding for tuberculosis and HIV in household contacts of patients with tuberculosis in South Africa. (2012) (97)
Impact of enhanced tuberculosis diagnosis in South Africa: A mathematical model of expanded culture and drug susceptibility testing (2008) (97)
Effectiveness of supervised, intermittent therapy for tuberculosis in HIV‐infected patients (1994) (97)
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs (2001) (93)
Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy (2010) (93)
Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. (2012) (90)
Differences in HIV Disease Progression by Injecting Drug Use in HIV-Infected Persons in Care (2004) (90)
Latent Mycobacterium tuberculosis Infection. (2015) (90)
Racial and Ethnic Differences in Outcome in Zidovudine-Treated Patients With Advanced HIV Disease (1991) (90)
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. (1999) (90)
Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. (2003) (88)
HIV-associated lung infections and complications in the era of combination antiretroviral therapy. (2011) (88)
Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. (2006) (88)
Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. (2015) (87)
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults (2008) (86)
Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults. (2006) (85)
Quantitative Analysis of a Urine-Based Assay for Detection of Lipoarabinomannan in Patients with Tuberculosis (2010) (84)
An Outbreak of Scabies in a Teaching Hospital Lessons Learned (2001) (84)
Clinical evaluation of the microscopic-observation drug-susceptibility assay for detection of tuberculosis. (2007) (83)
HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. (2009) (83)
Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. (2007) (83)
Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis (2002) (83)
Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. (2002) (83)
Guidelines for the management of community-acquired pneumonia (2000) (82)
The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model (2006) (81)
Does tuberculosis increase HIV load? (2004) (81)
Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention (2007) (81)
Predicting smear negative pulmonary tuberculosis with classification trees and logistic regression: a cross-sectional study (2006) (80)
Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. (2015) (80)
The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. (2009) (79)
Neutropenia and bacterial infection in acquired immunodeficiency syndrome. (1995) (79)
Validation of a Hierarchical Deterministic Record-Linkage Algorithm Using Data From 2 Different Cohorts of Human Immunodeficiency Virus-Infected Persons and Mortality Databases in Brazil (2008) (77)
Performance of the Microscopic Observation Drug Susceptibility Assay in Drug Susceptibility Testing for Mycobacterium tuberculosis (2002) (77)
Measurement of HIV risk behaviors among intravenous drug users. (1992) (77)
Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. (2011) (73)
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events (2008) (73)
High Prevalence of Pulmonary Tuberculosis but Low Sensitivity of Symptom Screening among HIV-Infected Pregnant Women in South Africa (2013) (72)
Mycobacteria and AIDS mortality. (1989) (72)
Adverse events from drug therapy for human immunodeficiency virus disease. (1996) (72)
Patient and health care system delays in pulmonary tuberculosis diagnosis in a low-incidence state. (2005) (72)
Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil (2008) (71)
Combining PMTCT With Active Case Finding for Tuberculosis (2006) (68)
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) Study (2010) (67)
Human T cell lymphotropic virus types I and II in intravenous drug users in San Francisco: risk factors associated with seropositivity. (1991) (66)
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? (2004) (66)
Recurrent tuberculosis: relapse, reinfection, and HIV. (2010) (65)
Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. (2000) (65)
Impact and Cost-Effectiveness of Culture for Diagnosis of Tuberculosis in HIV-Infected Brazilian Adults (2008) (64)
Active Tuberculosis Case-Finding Among Pregnant Women Presenting to Antenatal Clinics in Soweto, South Africa (2011) (63)
Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. (1992) (62)
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. (2015) (62)
Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. (2003) (62)
The Ancillary-Care Obligations of Medical Researchers Working in Developing Countries (2008) (62)
Functional status of persons with HIV infection in an ambulatory setting. (1994) (61)
Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations (2008) (60)
1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus (1999) (59)
Tuberculosis active case‐finding in a mother‐to‐child HIV transmission prevention programme in Soweto, South Africa (2003) (57)
Survival in an Urban HIV‐1 Clinic in the Era of Highly Active Antiretroviral Therapy: A 5‐Year Cohort Study (2003) (56)
Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group. (1991) (55)
Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. (2008) (55)
Latent tuberculosis infection among undergraduate medical students in Rio de Janeiro State, Brazil. (2005) (54)
Rectal leishmaniasis in a patient with acquired immunodeficiency syndrome. (1988) (54)
Living with AIDS. (1990) (54)
Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. (1996) (53)
Rapid detection of Pneumocystis carinii using a direct fluorescent monoclonal antibody stain (1990) (53)
Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity. (2003) (52)
Establishing a workplace antiretroviral therapy programme in South Africa (2007) (51)
Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial. (1988) (51)
Human Immunodeficiency Virus Infection in Women Attending an Inner‐City Prenatal Clinic: Ineffectiveness of Targeted Screening (1990) (50)
Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group. (1992) (50)
A Cluster-Randomized Trial of Provider-Initiated (Opt-Out) HIV Counseling and Testing of Tuberculosis Patients in South Africa (2008) (50)
Lack of sex difference in CD4 to HIV-1 RNA viral load ratio (1999) (49)
Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. (1989) (49)
Human immunodeficiency virus-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. (2001) (49)
Increasing incidence of avascular necrosis of the hip in HIV-infected patients. (2001) (48)
Controlled trial of active tuberculosis case finding in a Brazilian favela. (2010) (47)
‘ZS-MDR-TB' versus ‘ZR-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility (2012) (47)
Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. (1997) (47)
Pneumocystis Prophylaxis and Survival in Patients With Advanced Human Immunodeficiency Virus Infection Treated With Zidovudine (1992) (46)
Undiagnosed Tuberculosis Among HIV Clinic Attendees: Association With Antiretroviral Therapy and Implications for Intensified Case Finding, Isoniazid Preventive Therapy, and Infection Control (2012) (46)
Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS (1995) (46)
Long-term Safety and Efficacy of Zidovudine in Patients With Advanced Human Immunodeficiency Virus Disease (1991) (44)
Community-randomized trial of enhanced DOTS for tuberculosis control in Rio de Janeiro, Brazil. (2010) (44)
Changing Predictors of Mortality Over Time From cART Start: Implications for Care (2011) (43)
Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. Zidovudine Epidemiology Study Group. (1993) (43)
Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. (1999) (42)
Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz (2001) (42)
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials (2018) (42)
Errors in the treatment of tuberculosis in Baltimore. (2000) (42)
[HIV infection and tuberculosis]. (1991) (41)
Community DOT for tuberculosis in a Brazilian favela: comparison with a clinic model. (2007) (41)
Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa (2010) (41)
Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. (2005) (41)
The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. (1998) (41)
HIV, BLEACH, AND NEEDLE SHARING (1987) (40)
Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients (2017) (40)
Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. (2011) (40)
Analysis of Rifapentine for Preventive Therapy in the Cornell Mouse Model of Latent Tuberculosis (1999) (39)
Diagnostic Accuracy of a Urine Lipoarabinomannan Enzyme-Linked Immunosorbent Assay for Screening Ambulatory HIV-Infected Persons for Tuberculosis (2011) (38)
TB treatment: as simple as DOT? (2003) (37)
Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients (1996) (37)
A diagonal approach to building primary healthcare systems in resource‐limited settings: women‐centred integration of HIV/AIDS, tuberculosis, malaria, MCH and NCD initiatives (2012) (37)
HIV-related tuberculosis in a transgender network--Baltimore, Maryland, and New York City area, 1998-2000. (2000) (36)
Prevention of opportunistic infections in the era of improved antiretroviral therapy. (1997) (36)
Patient-nominated, community-based HIV treatment supporters: patient perspectives, feasibility, challenges, and factors for success in HIV-infected South African adults. (2013) (35)
Multidrug-resistant tuberculosis. (1992) (35)
Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation? (2015) (35)
Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group. (1992) (35)
Field Evaluation of a Rapid Immunochromatographic Test for Tuberculosis (2002) (34)
Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. (2011) (34)
Bacterial pneumonia in patients with human immunodeficiency virus infection. (1989) (34)
Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. (2008) (34)
Tuberculosis incidence among contacts of active pulmonary tuberculosis. (2009) (33)
Mortality Associated With Delays Between Clinic Entry and ART Initiation in Resource-Limited Settings: Results of a Transition–State Model (2013) (33)
Clinical Evaluation of the Microscopic Observation Drug Susceptibility Assay for Detection of Mycobacterium tuberculosis Resistance to Isoniazid or Rifampin (2007) (32)
Time of exposure and risk of HIV infection in homosexual partners of men with AIDS. (1988) (32)
Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. (2002) (32)
Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study (2018) (31)
Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. (1991) (31)
Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa (2014) (30)
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis (2016) (30)
South African TB nurses' experiences of provider-initiated HIV counseling and testing in the Eastern Cape Province: a qualitative study (2010) (30)
Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection. (1993) (30)
Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. (1994) (29)
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. (2020) (29)
Discrepancies between women's personal interview data and medical record documentation of illicit drug use, sexually transmitted diseases, and HIV infection. (1992) (29)
Use of audio computer-assisted self-interviews to assess tuberculosis-related risk behaviors. (2001) (29)
Vitamin A status in HIV infection (1993) (29)
Factors associated with pulmonary impairment in HIV-infected South African adults (2017) (29)
Comparison of C18-Carboxypropylbetaine and Standard N-Acetyl-l-Cysteine-NaOH Processing of Respiratory Specimens for Increasing Tuberculosis Smear Sensitivity in Brazil (2002) (29)
Confronting multidrug-resistant tuberculosis. (2012) (28)
AIDS-Related Tuberculosis in Rio de Janeiro, Brazil (2008) (28)
Impact of Isoniazid Preventive Therapy for HIV-Infected Adults in Rio de Janeiro, Brazil: An Epidemiological Model (2014) (27)
Lymphadenopathy in asymptomatic patients seropositive for HIV. (1987) (26)
Yield of household contact tracing for tuberculosis in rural South Africa (2018) (26)
Tuberculosis control in a socially vulnerable area: a community intervention beyond DOT in a Brazilian favela. (2013) (26)
Point-of-care Arkansas method for measuring adherence to treatment with isoniazid. (2010) (26)
Undiagnosed TB in adults dying at home from natural causes in a high TB burden setting: a post-mortem study. (2015) (26)
Risk factors for cryptococcal meningitis in HIV-infected patients. (1999) (26)
Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa (2015) (26)
Progressive multifocal leukoencephalopathy in AIDS. (1990) (26)
Twelve-monthly versus six-monthly radiological screening for active case-finding of tuberculosis: a randomised controlled trial (2010) (26)
The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. (1995) (25)
Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. (1997) (25)
Intensified case finding for tuberculosis in prevention of mother-to-child transmission programs: a simple and potentially vital addition for maternal and child health. (2009) (25)
A call to action for concentrated HIV epidemics (2014) (25)
Long-Term Effectiveness of Diagnosing and Treating Latent Tuberculosis Infection in a Cohort of HIV-Infected and At-Risk Injection Drug Users (2008) (25)
Diagnostic yield of peripheral lymph node needle-core biopsies in HIV-infected adults with suspected smear-negative tuberculosis. (2005) (25)
Risk Factors for Kaposi's Sarcoma in Patients With Advanced Human Immunodeficiency Virus Disease Treated With Zidovudine (1994) (25)
Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis (2018) (25)
Preventing Tuberculosis Among HIV-Infected Pregnant Women in Lesotho: The Case for Rolling Out Active Case Finding and Isoniazid Preventive Therapy (2014) (24)
QuantiFERON-TB Gold In-Tube for the detection of Mycobacterium tuberculosis infection in children with household tuberculosis contact. (2011) (24)
Survey of tuberculosis drug resistance among Tibetan refugees in India. (2014) (24)
Zidovudine therapy and health resource utilization in AIDS. (1994) (23)
CD4 and Viral Load Dynamics in Antiretroviral-Naïve HIV-Infected Adults from Soweto, South Africa: A Prospective Cohort (2014) (23)
Impact of the 1993 revision of the AIDS case definition on the prevalence of AIDS in a clinical setting (1993) (23)
Estimating the extent of underreporting of mortality among HIV-infected individuals in Rio de Janeiro, Brazil. (2011) (23)
Risk Factors for Developing Active Tuberculosis After the Treatment of Latent Tuberculosis in Adults Infected With Human Immunodeficiency Virus (2014) (23)
Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment. (2013) (23)
Improved Detection of Tuberculosis and Multidrug-Resistant Tuberculosis among Tibetan Refugees, India (2016) (22)
How research can help control tuberculosis. (2009) (22)
Characteristics of injection drug users who utilize tuberculosis services at sites of the baltimore city needle exchange program (2002) (22)
A Randomized, Double-Blind, Dose-ranging Study in Patients with AIDS (2009) (22)
Racial heterogeneity of HIV antigenemia in people with HIV infection. (1991) (22)
Resistance to Tenofovir-Based Regimens during Treatment Failure of Subtype C HIV-1 in South Africa (2013) (22)
Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa (2016) (22)
Predictors of delay in the diagnosis and treatment of suspected tuberculosis in HIV co-infected patients in South Africa. (2013) (22)
Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in Rural Malawi: A Cluster Randomized Trial (Chepetsa) (2018) (21)
Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study. (2014) (21)
The cost-effectiveness of DOTS in urban Brazil. (2007) (21)
Isoniazid preventive therapy for HIV-infected people: evidence to support implementation (2010) (21)
Physician adherence to guidelines for tuberculosis and HIV care in Rio de Janeiro, Brazil. (2011) (21)
Clinical standards for the diagnosis, treatment and prevention of TB infection (2022) (20)
Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users. (1992) (20)
Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control. (2014) (20)
Lack of Association between Acyclovir Use and Survival in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine (1995) (19)
Treatment of Chronic Infections with Rifamycins: Is Resistance Likely To Follow? (2003) (19)
Building Clinical Trials Capacity for Tuberculosis Drugs in High-Burden Countries (2007) (19)
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB (2021) (19)
Prevalence of anti-tuberculosis drug resistance in an HIV/AIDS reference hospital in Rio de Janeiro, Brazil. (2009) (18)
The association between symptoms and microbiologically defined response to tuberculosis treatment. (2013) (18)
Widespread HIV counseling and testing linked to a community-based tuberculosis control program in a high-risk population. (1996) (18)
General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including Acute Retroviral Syndrome and Oral, Cutaneous, Renal, Ocular, Metabolic, and Cardiac Diseases) (2015) (18)
Screening for Tuberculosis Among Adults Newly Diagnosed With HIV in Sub-Saharan Africa: A Cost-Effectiveness Analysis (2015) (18)
Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis (2019) (18)
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. (2020) (18)
Intramedullary tuberculoma in a patient with HIV infection. (1992) (18)
Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection (2019) (18)
Smoking cessation in patients with HIV. (1994) (17)
Isoniazid Preventive Therapy and Pregnancy Outcomes in Women Living With Human Immunodeficiency Virus in the Tshepiso Cohort (2019) (17)
Infections due to encapsulated bacteria, Salmonella, Shigella, and Campylobacter. (1988) (17)
Understanding and retention of trial-related information among participants in a clinical trial after completing the informed consent process (2014) (17)
Cotrimoxazole Prophylaxis and Tuberculosis Risk among People Living with HIV (2014) (17)
High Prevalence of Active and Latent Tuberculosis in Children and Adolescents in Tibetan Schools in India: The Zero TB Kids Initiative in Tibetan Refugee Children (2018) (16)
Empiric diagnosis of Pneumocystis pneumonia. (1987) (16)
Improvements in treatment success rates with directly observed therapy in Rio de Janeiro City. (2006) (16)
The clinical pharmacokinetics of rifabutin. Discussion (1996) (16)
Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients. (1999) (16)
Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi. (2018) (16)
Preventing tuberculosis in people with HIV-no more excuses. (2017) (15)
Immunotherapy for tuberculous pericarditis. (2014) (15)
Mycobacterial infections and HIV (1993) (15)
Survival of HIV patients with tuberculosis started on simultaneous or deferred HAART in the THRio cohort, Rio de Janeiro, Brazil (2014) (15)
Prevalent Tuberculosis at HIV Diagnosis in Rio de Janeiro, Brazil: The TB/HIV in Rio (THRio) Cohort (2014) (15)
The ethics of testing a test: randomized trials of the health impact of diagnostic tests for infectious diseases. (2012) (15)
Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence (2012) (15)
Evolution of Chest Radiographs in Treated Patients with Pulmonary Tuberculosis and HIV Infection (1994) (15)
Durable HIV RNA resuppression after virologic failure while remaining on a first‐line regimen: a cohort study (2014) (14)
Advances in clinical trial design: Weaving tomorrow’s TB treatments (2020) (14)
Tuberculosis and Hepatic Steatosis Are Prevalent Liver Pathology Findings among HIV-Infected Patients in South Africa (2015) (14)
Quality of life among people treated for tuberculosis and human immunodeficiency virus in Rio de Janeiro, Brazil. (2013) (13)
Tuberculosis chemotherapy: still a double-edged sword. (2003) (13)
Diagnostic accuracy of plasma kynurenine/tryptophan ratio, measured by enzyme-linked immunosorbent assay, for pulmonary tuberculosis. (2020) (12)
Integrated Source Case Investigation for Tuberculosis (TB) and HIV in the Caregivers and Household Contacts of Hospitalised Young Children Diagnosed with TB in South Africa: An Observational Study (2015) (12)
Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. (2015) (12)
Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV (2019) (12)
Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: Did close examination of the trees obscure our view of the wood? (2010) (12)
HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa (2009) (12)
Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis. (2016) (12)
Prenatal HIV-antibody testing and the meaning of consent. (1994) (11)
Tuberculosis screening in an at-risk immigrant Hispanic population in Baltimore city: an academic health center/local health department partnership. (2002) (11)
Annual Tuberculosis Preventive Therapy for Persons With HIV Infection (2021) (11)
Annual Tuberculosis Preventive Therapy for Persons With HIV Infection (2021) (11)
Cost-Effectiveness of Prophylaxis for Mycobacterium avium Complex Disease (1997) (11)
Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening. (2016) (11)
A RANDOMIZED TRIAL OF 2 MONTHS OF RIFAMPIN (RIF) AND PYRAZINAMIDE (PZA) VERSUS 12 MONTHS OF ISONIAZID (INH) FOR THE PREVENTION OF TUBERCULOSIS (TB) IN HIV–POSITIVE (+), PPD+ PATIENTS (ABSTRACT) (1998) (10)
New developments in the treatment of latent tuberculosis. (2000) (10)
Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil. (2013) (10)
Health effects and exposure assessment of aerosolized pentamidine handlers. (1993) (10)
Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants (2017) (10)
Mycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease (1998) (10)
Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. (1999) (10)
Moxifloxacin in the Initial Therapy of Tuberculosis: A Randomized, Phase 2 Trial (2010) (10)
Additive effects of isoniazid preventive therapy and HAART. (2009) (9)
Epidemiology of Tuberculosis and HIV (2012) (9)
Duration of the survival benefit of zidovudine therapy in HIV infection. (1996) (9)
Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV. (2019) (9)
Comparison of nosocomial infections due to Staphylococcus aureus and enterococci in a general hospital. (1987) (9)
Management of adult active tuberculosis disease in era of HIV pandemic, current practices and future perspectives. (2011) (9)
Natural history of advanced HIV disease in patients treated with zidovudane (1992) (9)
70 years of TB Prevention: Efficacy, Effectiveness, Toxicity, Durability and Duration. (2019) (9)
Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens. (1996) (8)
Latent tuberculous infection in schoolchildren and contact tracing in Matlosana, North West Province, South Africa. (2015) (8)
Osteomyelitis due to mycobacterium kansasii and mycobacterium avium complex in an HIV-infected patient (1994) (8)
Prior antimicrobials and staphylococcal bacteremia in HIV‐infected patients (1997) (8)
Treating multidrug-resistant tuberculosis: compliance and side effects. (1994) (8)
Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease. (1997) (8)
Diagnostic accuracy of three clinical case definitions for advanced HIV disease (1992) (8)
MTBDRplus results correlate with treatment outcome in previously treated tuberculosis patients. (2015) (8)
CXCR6 gene characterization in two ethnically distinct South African populations and association with viraemic disease control in HIV-1-infected black South African individuals. (2017) (8)
Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis (2021) (8)
Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. (2017) (8)
Applying ethical principles to international community-based research: a case study from the Consortium to Respond Effectively to the AIDS-TB Epidemic (CREATE) . (2014) (7)
HIV becomes world's leading infectious cause of death. (1999) (7)
Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies (2019) (7)
Adverse reactions to therapy for HIV infection. (1995) (7)
The scientific response to TB – the other deadly global health emergency (2022) (7)
Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment. (2012) (7)
Efficacy of engineering controls in reducing occupational exposure to aerosolized pentamidine. (1992) (7)
Delay in seeking care for tuberculosis symptoms among adults newly diagnosed with HIV in rural Malawi (2018) (7)
Tuberculosis and HIV disease. (1993) (6)
The efficacy of zidovudine is time limited. (1994) (6)
Human leukocyte antigen associations with protection against tuberculosis infection and disease in human immunodeficiency virus-1 infected individuals, despite household tuberculosis exposure and immune suppression. (2020) (6)
Age-related changes in the immune function of HIV-1 seropositive adults (1991) (6)
Progressive Multifocal Leukoencephalopathy in AIDS (1991) (6)
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. (2020) (6)
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine (2020) (6)
The FCGR2C allele that modulated the risk of HIV-1 infection in the Thai RV144 vaccine trial is implicated in HIV-1 disease progression (2018) (6)
Acute effects of a nucleoside analog dideoxyinosine (DDI) on the pancreas. (1992) (6)
DOTS and drug resistance: a silver lining to a darkening cloud. (1999) (6)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. Longcope Firm of the Osler Medical Housestaff. (1996) (5)
First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India (2022) (5)
Zidovudine and the natural history of AIDS [1] (1991) (5)
Cis-regulatory genetic variants in the CCR5 gene and natural HIV-1 control in black South Africans. (2019) (5)
Improving TPT Uptake: A Cluster-Randomized Trial of Symptom-Based Versus Tuberculin Skin Test-Based Screening of Household Tuberculosis Contacts Less than 5 Years of Age. (2020) (5)
Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries (2021) (5)
A protective guard for use during reconstruction of the auricle. (1974) (5)
Plasma kynurenine-to-tryptophan ratio, a highly sensitive blood-based diagnostic tool for Tuberculosis in HIV-infected pregnant women. (2021) (4)
Systemic DPP4/CD26 is associated with natural HIV-1 control: Implications for COVID-19 susceptibility (2021) (4)
Guidelines for the design and conduct of AIDS clinical trials. AIDS Clinical Trials Group. (1993) (4)
Applying Risk-Benefit Analysis to Outcomes in TB Clinical Trials. (2020) (4)
Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda (2020) (4)
Cost‐effectiveness of a 12 country‐intervention to scale up short course TB preventive therapy among people living with HIV (2020) (4)
Evaluation of an HIV/AIDS education program in an urban prenatal clinic. (1997) (4)
CD4 count stratification to guide tuberculosis preventive therapy for people living with HIV. (2019) (4)
Quality of life among people treated for tuberculosis and human immunodeficiency virus in Rio de Janeiro, Brazil [Short communication]. (2013) (3)
Patient‐incurred cost of inpatient treatment for Tuberculosis in rural Malawi (2020) (3)
Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. (1995) (3)
The importance of doing HIV research in developing countries (1998) (3)
Prevention of opportunistic infections in patients with HIV. (1990) (3)
The world AIDS conference in Durban, South Africa--science, politics, and health. (2000) (3)
HIV Antigen Variability in ARC/AIDS (1991) (3)
Survival after Active Tuberculosis in Patients with HIV Infection: Reply (1990) (3)
Control of tuberculosis during aerosol therapy administration. (1991) (3)
High prevalence of rifampin-resistant tuberculosis in mountainous districts of India. (2020) (3)
1125 Hepatotoxicity associated with the antiretroviral therapy (ART) containing protease inhibitors (PIS) with or without pharmacokinetic boosting by low-dose ritonavir (RTV) (2003) (3)
Cryptococcosis and other fungal infections (histoplasmosis and coccidioidomycosis) in HIV-infected patients (2008) (3)
Prevention of tuberculosis in HIV-1 (1998) (3)
RICH2 is implicated in viraemic control of HIV-1 in black South African individuals. (2017) (3)
Handbook of Tuberculosis (2017) (3)
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy. (2002) (3)
MEMS devices to measure adherence among HIV infected patients (1997) (2)
The effectiveness of combination antiretroviral therapy in clinical practice (1997) (2)
Erratum: Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis (American Journal of Respiratory and Critical Care Medicine (2004) 169 (421-426)) (2005) (2)
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. (2023) (2)
Why Blame Private Practitioners (2001) (2)
The impact of bone marrow stromal antigen-2 (BST2) gene variants on HIV-1 control in black South African individuals. (2020) (2)
Detection and molecular characterization of urinary tract HIV-1 populations (2019) (2)
Survival with AIDS in New York. (1988) (2)
Outcomes of Angioplasty vs Thrombolysis by Hospital Angioplasty (2)
Antimicrobial activity of rifabutin. Discussion (1996) (2)
Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus. (1996) (2)
Survival in XDR TB: shifting the curve and shifting the paradigm. (2011) (2)
Health-related quality of life of inpatients and outpatients with TB in rural Malawi. (2020) (2)
Pneumocystis carinii pneumonia: diagnosis and management. (1990) (2)
Eff ect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro , Brazil : a stepped wedge , cluster-randomised trial (2013) (2)
Risk of developing active tuberculosis following tuberculosis screening and preventive therapy for Tibetan refugee children and adolescents in India: An impact assessment. (2021) (2)
Contribution Of Country Of Birth To The Transmission Of Mycobacterium Tuberculosis In New York City (NYC) (2012) (2)
No news is good news: opportunistic infections. (1998) (2)
Empirical Antituberculosis Therapy in Advanced HIV Disease - Too Much, Too Late. (2020) (2)
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply. (2019) (2)
Correction: CD4 and Viral Load Dynamics in Antiretroviral-Naïve HIV-Infected Adults from Soweto, South Africa: A Prospective Cohort (2015) (2)
Overview of Tuberculosis (2017) (2)
Gender differences in indices of opioid dependency and medical comorbidity in a population of hospitalized HIV-infected African-Americans. (2004) (2)
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus (2023) (2)
Subclinical tuberculosis and adverse infant outcomes in pregnant women with HIV. (2020) (2)
Intravenous Cocaine and HIV Infection-Reply (1989) (1)
Prophylaxis for Opportunistic Infections (1995) (1)
Randomized controlled study of the effectiveness of annual and 6-monthly screening with mass miniature radiography (MMR) for the active case-finding of cardiopulmonary TB patients (2003) (1)
On the analysis of tuberculosis studies with intermittent missing sputum data (2015) (1)
Drug Resistance and the Treatment of Upper Respiratory Infections (1999) (1)
Communications to the EditorThe Effect of Prophylaxis on the Outcome of HIV-Associated Pneumocystis carinii Pneumonia (1996) (1)
A Partially-Randomised Phase 3 Trial of Pretomanid, Moxifloxacin and Pyrazinamide in Combination for the Treatment of Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis (2020) (1)
HIV disease and its treatment: current status and future prospects (1996) (1)
Mycobacterium avium complex and HIV. (1995) (1)
Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis (2019) (1)
Immunotherapy for tuberculous pericarditis. (2014) (1)
Clarithromycin Therapy for Mycobacterium avium Complex Bacteremia (1995) (1)
Whole-blood Interferon-γ Release Assay Versus the TST: Newer Not Better (2003) (1)
The effect of acute infections on HIV-1 viral load and the expression of immune activation markers among HIV-infected adults (1997) (1)
NONTUBERCULOUS MYCOBACTERIAL INFECTIONS IN HIV DISEASE (1994) (1)
Impact of HIV and its treatment on chronic hepatitis C in hemophiliacs (1994) (1)
Post-2015 tuberculosis strategies in a pre-2015 world. (2013) (1)
Pregnancy in Women With HIV in a Tuberculosis Preventive Therapy Trial (2022) (1)
Post-trial perceptions of a symptom-based TB screening intervention in South Africa: implementation insights and future directions for TB preventive healthcare services (2020) (1)
TB and HIV: challenges and progress. (2002) (1)
WHEN TO INITIATE HAART, HIV DISEASE PROGRESSION ACCORDING TO CD4 1EVEL AT INITIATION OF THERAPY AMONG PERSONS WITH DURABLEVIROLOGIC SUPPRESSION (2002) (1)
Empirical Diagnosis of Pneumocystis carinii Pneumonia-Reply (1988) (1)
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing (2022) (1)
Tuberculosis and HIV/AIDS in South Africa : tuberculosis (2000) (1)
Non-tuberculous mycobacteria in HIV-infected patients: geographic, behavioural, and immunological factors – Authors' reply (2005) (1)
PROPHYLAXIS FOR OPPORTUNISTIC INFECTIONS. AUTHORS' REPLY (1995) (1)
HIV testing urged for pregnancy. (1991) (1)
Impact of the 1993 revision of the CDC case definition on the performance of the WHO and PAHO clinical case definitions for AIDS (1993) (1)
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review (2022) (1)
HumanImmunodeficiency VirusInfection in Heterosexual Intravenous DrugUsersinSanFrancisco (1987) (1)
Cryptosporidiosis in AIDS: Correlates of disease and survival (1997) (1)
Tuberculosis and HIV infection--new opportunities for an old pathogen. (1989) (1)
Factors associated with non-completion of TB preventive treatment in Brazil. (2023) (0)
Evaluation of a Test for Measuring Adherence to Treatment for Latent Tuberculosis Infection. (2009) (0)
Trials of Tuberculosis-Preventive Therapy in People with HIV Infection (2020) (0)
THE EFFICACY OF ZIDOVUDINE IS TIME LIMITED. AUTHORS' REPLY (1994) (0)
Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349). (2022) (0)
Tolerance of short course tb chemoprophylaxis in hiv infected individuals (1991) (0)
HIV/Tuberculosis Co-Infection Deadly Synergy (2009) (0)
Tuberculosis (2020) (0)
Non-tuberculous mycobacteria in HIV-infected patients: geographic behavioural and immunological factors. Authors reply [letter] (2005) (0)
Oil spills and offshore drilling. (1978) (0)
HealthEffectsand ExposureAssessment of AerosolizedPentamidineHandlers * (0)
Double Trouble: Managing HIV-related TB (2015) (0)
Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics Guidance (2018) (0)
Neutropenia and latrogenic Neutrophil Dysfunction in Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome-Reply (1996) (0)
Reflection and Reaction (2005) (0)
Community-Based Respiratory Symptom Evaluation In A Brazilian Favela (2011) (0)
Burden Of Lung Disease And Risks For Lung Disease Among Persons Living With HIV In Soweto, South Africa (2011) (0)
Epidemiology in History Seventy Years of Tuberculosis Prevention: Ef ﬁ cacy, Effectiveness, Toxicity, Durability, and Duration (2019) (0)
Selected Topics from the 9th Conference on Retroviruses and Opportunistic Infections (2002) (0)
Iconographies supplémentaires de l'article : A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users (2011) (0)
Epidemiology of HIV infection among hemophiliacs and importance of CD4+ cells as surrogate markers (1994) (0)
Factors associated with tuberculosis preventive treatment incompletion: a retrospective Cohort. (2023) (0)
The impact of M. tuberculosis infection on subsequent disseminated MAC disease in KV-infected persons (1997) (0)
Moxifloxacin versus ethambutol in initial tuberculosis treatment – Authors' reply (2009) (0)
Tuberculosis: a deadly and neglected disease in the COVID-19 era (2022) (0)
Report on HIV/TB Research meeting in conjunction with the 2019 CROI Conference on Retroviruses and Opportunistic Infections (2019) (0)
Care-Seeking Behavior for Respiratory Symptoms in a Brazilian Favela (SLUM) (2006) (0)
The FCGR2C allele that modulated the risk of HIV-1 infection in the Thai RV144 vaccine trial is implicated in HIV-1 disease progression (2018) (0)
Now that health care is worth something. (1989) (0)
The Mid-Atlantic Centers for AIDS Research (CFAR) Consortium (MACC): Promoting HIV Science through Regional Collaboration. (2021) (0)
Differential Incidence And Patient Characteristics Of Tuberculosis (TB) By Country Of Birth In New York City (NYC), 2001-2008 (2012) (0)
Resource Management on the OCS: The State Role (1978) (0)
Tuberculosis and HIV disease. (1991) (0)
Data from: Factors associated with pulmonary impairment in HIV-infected South African adults (2017) (0)
A-111 Controlling the impact of HIV-related tuberculosis (2016) (0)
Risk factors for bacterial pneumonia in MV disease (1997) (0)
Chapter 16 – Pulmonary Complications of HIV Infection (2004) (0)
New developments in the treatment of latent tuberculosis [The Eddie O'Brien Lecture]. (2000) (0)
Comparing rates of mycobacterial clearance in sputum smear-negative and smear-positive adults living with HIV (2021) (0)
Taking the long view on the CREATE studies' findings. (2014) (0)
How research can help control tuberculosis. (2010) (0)
Reply to “At the crossroads between early or delayed antiretroviral therapy initiation during TB/HIV coinfection” (2014) (0)
Contributors (2015) (0)
Survival with AIDS in New York [letter] (1988) (0)
Africa is facing the worst tuberculosis epidemic since the advent of the antibiotic era . Driven by a generalized human immunodeficiency virus ( HIV ) epidemic and compounded by weak health (2008) (0)
TREATMENT OF LATENT TUBERCULOSIS IN HIV INFECTED ADULTS (2014) (0)
“Symptom Screening is Easier, but You Can Miss…”: Perceptions of Nurse-led Symptom-based Screening to Promote Tuberculosis Preventive Therapy in the Context of a Cluster Randomized Trial in South Africa (2020) (0)
Appropriate diagnosis and use of antimicrobial therapy in treating upper respiratory infections (1999) (0)
PREVIOUSLY UNRECOGNIZED HIV INFECTION AMONG HOSPITALIZED PATIENTS (1996) (0)
Plasma indoleamine 2,3-dioxygenase, a highly sensitive blood-based screening tool for active tuberculosis disease in HIV-infected pregnant women (2020) (0)
Reply: (2002) (0)
The impact of contact evaluation and TB preventive therapy on TB incidence. (2021) (0)
Improving Tuberculosis Preventive Therapy Uptake: A Cluster-randomized Trial of Symptom-based Versus Tuberculin Skin Test–based Screening of Household Tuberculosis Contacts Less Than 5 Years of Age (2020) (0)
Opportunistic infections. (2000) (0)
Chapter 29 – Cryptococcosis and other fungal infections (histoplasmosis and coccidioidomycosis) in HIV-infected patients (2012) (0)
Tuberculosis and diabetes mellitus: is vitamin D the missing link? (2010) (0)
Update on opportunistic infections. (2000) (0)
Topics in Primary Care Medicine Prophylaxis Against Opportunistic Infections in Patients Infected With the Human Immunodeficiency Virus (2005) (0)
Reflection and Reaction (2005) (0)
Brief Report: Yield of Repeat Tuberculin Skin Testing for People Living With HIV in Brazil (2021) (0)
Inhaled Glucocorticoids and Adult Height (2012) (0)
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase TB Trials. (2023) (0)
AIDS turns 20: reflections on a brief but extraordinary history. (2001) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard E. Chaisson?

Richard E. Chaisson is affiliated with the following schools:

Richard E. Chaisson's Academic­Influence.com Rankings

Richard E. Chaisson's Degrees

Why Is Richard E. Chaisson Influential?

Richard E. Chaisson's Published Works

Published Works

What Schools Are Affiliated With Richard E. Chaisson?

Richard E. Chaisson's AcademicInfluence.com Rankings